by GlobeNewsWire | Jul 12, 2016 | Globe Newswire
BOSTON, July 12, 2016 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced plans for a Phase I adoptive cellular therapy clinical trial utilizing autologous T cells...
by GlobeNewsWire | Jul 1, 2016 | Globe Newswire
PHILADELPHIA, July 01, 2016 (GLOBE NEWSWIRE) — Spark Therapeutics (NASDAQ:ONCE) announced today the publication in The Lancet of long-term data from a Phase 1 trial of voretigene neparvovec (SPK-RPE65), its most advanced product candidate which has received...
by GlobeNewsWire | Jun 29, 2016 | Globe Newswire
EXTON, Pa., June 29, 2016 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ:FCSC) today announced significant cost savings are expected from the wind-down of its azficel-T operations and that the Company is focusing its efforts and resources on its gene therapy...
by GlobeNewsWire | Jun 27, 2016 | Globe Newswire
BOSTON, June 27, 2016 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the successful completion of enrollment in the first and second dosing cohorts as well as the...
by GlobeNewsWire | Jun 23, 2016 | Globe Newswire
IRVINE, Calif., June 23, 2016 (GLOBE NEWSWIRE) — MRI Interventions, Inc. (OTCQB:MRIC), a commercial stage medical device company focused on creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain,...